N. Pemmaraju

M. Konopleva, H. Kantarjian, Xuelin Huang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge.

N. Daver, S. O'brien, N. Pemmaraju, 2014, Clinical lymphoma, myeloma & leukemia.

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

M. Konopleva, O. Frankfurt, F. Garnache-Ottou, 2014, Blood.

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

M. Andreeff, J. Dipersio, O. Frankfurt, 2015 .

Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.

M. Konopleva, M. Andreeff, H. Kantarjian, 2014 .

Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.

M. Konopleva, M. Andreeff, K. Bhalla, 2019, Journal of Clinical Oncology.

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

M. Konopleva, H. Kantarjian, K. Patel, 2020, American journal of hematology.

Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.

M. Konopleva, M. Andreeff, K. Bhalla, 2020, Blood cancer discovery.

Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

R. Collins, M. Konopleva, Z. Estrov, 2016 .

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Z. Estrov, H. Kantarjian, J. Cortes, 2014 .

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

S. Verstovsek, Jacqueline S. Garcia, C. Harrison, 2020 .

MPN-377: Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis

S. Verstovsek, C. Brooks, M. Talpaz, 2020 .

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A. Lane, N. Pemmaraju, Vikas Gupta, 2016, Current Hematologic Malignancy Reports.

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

G. Fuller, M. Konopleva, H. Kantarjian, 2017, American journal of hematology.

8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms.

L. Medeiros, Shaoying Li, N. Pemmaraju, 2018, Leukemia research.

Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.

H. Kantarjian, S. Verstovsek, J. Khoury, 2013, Blood.

Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome

M. Konopleva, N. Pemmaraju, J. Lopez-Mattei, 2021, JACC. CardioOncology.

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, Leukemia & lymphoma.

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Leukemia research.

#JACCCardioOnc

Sherry‐Ann Brown, N. Pemmaraju, N. Reza, 2021, JACC: CardioOncology.

Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia

Koichi Takahashi, E. Jabbour, N. Daver, 2016, American journal of hematology.

Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Antibody-Drug Conjugates in Myeloid Leukemias.

N. Daver, N. Pemmaraju, Jayastu Senapati, 2022, Cancer journal.

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, American journal of hematology.

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

M. Konopleva, G. Garcia-Manero, T. Kadia, 2022, Blood advances.

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

J. Welch, M. Konopleva, M. Andreeff, 2020, Haematologica.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, S. Colla, H. Kantarjian, 2018, Blood.

Influence of IDH on FLT3-ITD status in newly diagnosed AML

H. Kantarjian, F. Ravandi, N. Daver, 2017, Leukemia.

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Deanne M. Taylor, Xiaoping Su, Xiuping Liu, 2022, Nature Communications.

Impact of SF3B1 mutation in myelofibrosis

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2022, Leukemia & lymphoma.

Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD

Z. Estrov, M. Andreeff, H. Kantarjian, 2013, British journal of haematology.

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

M. Konopleva, H. Kantarjian, J. Cortes, 2020 .

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.

Naveen Garg, M. Konopleva, Z. Estrov, 2021, JAMA oncology.

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.

G. Borthakur, M. Keating, J. Burger, 2019, Journal of geriatric oncology.

Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia.

A. Rashid, L. Byers, D. Tan, 2020, Leukemia research.

PET‐positive lymphadenopathy in CLL—Not always Richter transformation

L. Jeffrey Medeiros, Z. Estrov, P. Jain, 2017, American journal of hematology.

Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia

Z. Estrov, P. Jain, Koichi Takahashi, 2015, American journal of hematology.

Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens

T. Kadia, F. Ravandi, G. Borthakur, 2022, American journal of hematology.

Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.

L. Chin, A. Protopopov, A. Futreal, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

T. Kadia, F. Ravandi, E. Jabbour, 2020, Leukemia & lymphoma.

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis—TAFRO syndrome

Z. Estrov, S. Verstovsek, K. Patel, 2015, American journal of hematology.

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Cancer.

Circulating Tumor DNA in Lymphoma Monitoring : Fantasy , Fad , or Fact ?

M. Konopleva, N. Pemmaraju, 2018 .

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

H. Kantarjian, J. Cortes, T. Manshouri, 2015, Leukemia research.

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2019, Blood.

Primary autoimmune myelofibrosis (MF) with high‐grade peripheral T‐cell lymphoma (PTCL) NOS

S. Verstovsek, P. Jain, C. Bueso-Ramos, 2013, European journal of haematology.

Editorial overview: Emerging importance of social media for real-time communication in the modern medical era.

N. Pemmaraju, 2017, Seminars in hematology.

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Blood.

Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation

T. Kadia, F. Ravandi, E. Jabbour, 2018, Journal of Clinical Pathology.

Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, American journal of hematology.

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.

Philip R. Cohen, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

Topoisomerase II inhibitors in AML: past, present, and future

G. Borthakur, N. Pemmaraju, M. Economides, 2019, Expert opinion on pharmacotherapy.

Chronic myelomonocytic leukemia: Forefront of the field in 2015.

G. Garcia-Manero, N. Pemmaraju, A. Nazha, 2015, Critical reviews in oncology/hematology.

Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis

Hannah C. Beird, N. Ajami, J. Petrosino, 2015, PloS one.

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.

T. Barbui, M. Robin, I. Yakoub-Agha, 2022, The Lancet. Haematology.

Treating Leukemia in the Time of COVID-19

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Acta Haematologica.

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, The Lancet. Haematology.

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022 .

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study

S. Devlin, S. Verstovsek, T. Kadia, 2018, Blood.

Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

P. Qiu, K. Rajapakshe, C. Coarfa, 2016, Leukemia.

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, American journal of hematology.

Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, American journal of hematology.

Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Cancer.

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

H. Kantarjian, S. Verstovsek, E. Jabbour, 2019, Leukemia & lymphoma.

SMAC mimetics as potential cancer therapeutics in myeloid malignancies

S. Verstovsek, N. Pemmaraju, B. Carter, 2019, British journal of haematology.

Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy

C. Brooks, N. Pemmaraju, M. Patnaik, 2021, Leukemia & lymphoma.

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Z. Ju, M. Konopleva, F. Meric-Bernstam, 2023, Nature Medicine.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

J. Welch, M. Konopleva, Z. Estrov, 2020, The Lancet. Haematology.

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Z. Estrov, Jianhua Zhang, Xingzhi Song, 2019, Blood Cancer Journal.

Tagraxofusp in Blastic Plasmacytoid Dendritic‐Cell Neoplasm

M. Konopleva, H. Kantarjian, A. Lane, 2019, The New England journal of medicine.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

K. Rajapakshe, C. Coarfa, M. Konopleva, 2019, Blood Cancer Journal.

TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow

L. Jeffrey Medeiros, M. Routbort, K. Patel, 2013, American journal of hematology.

Erythroleukemia-historical perspectives and recent advances in diagnosis and management.

G. Borthakur, J. Khoury, N. Pemmaraju, 2017, Blood reviews.

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

W. Hung, S. Jiang, J. Cortes, 2017, Scientific Reports.

Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms.

S. Verstovsek, N. Pemmaraju, N. Chen, 2021, Hematology/oncology clinics of North America.

CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies

M. Konopleva, N. Pemmaraju, L. Bover, 2021, Leukemia & lymphoma.

Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm

N. Pemmaraju, S. Lee, Deborah McCue, 2020, Expert review of anticancer therapy.

Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

N. Pemmaraju, D. Rizzieri, M. Economides, 2019, Current Hematologic Malignancy Reports.

Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm

M. Konopleva, N. Pemmaraju, M. Economides, 2019, Therapeutic advances in hematology.

Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm.

N. Pemmaraju, E. Atallah, G. S. Guru Murthy, 2018, Leukemia research.

Update on the Biology and Treatment Options for Hairy Cell Leukemia

P. Jain, F. Ravandi, N. Pemmaraju, 2014, Current Treatment Options in Oncology.

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

G. Garcia-Manero, Xuelin Huang, F. Ravandi, 2023, American journal of hematology.

Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Cancer.

Significance of recurrence of minimal residual disease detected by multi‐parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Clinical and molecular characterization of myeloid sarcoma without medullary leukemia

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Leukemia & lymphoma.

Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.

V. Baladandayuthapani, H. Kantarjian, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical lymphoma, myeloma & leukemia.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Leukemia.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, Cancer.

Flow cytometric quantification of neutrophil extracellular traps: Limitations of the methodological approach

E. Jabbour, C. Bueso-Ramos, N. Pemmaraju, 2016, American journal of hematology.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Naveen Garg, Rashmi Kanagal-Shamanna, Prithviraj Bose, 2019, The New England journal of medicine.

Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM

R. Mesa, N. Pemmaraju, Vikas Gupta, 2016, Current Hematologic Malignancy Reports.

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Blood.

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.

K. Rezvani, D. Marin, H. Kantarjian, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Blood.

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

K. Pradhan, S. Demo, A. Verma, 2023, Research square.

Sudden blastic transformation in treatment‐free remission chronic myeloid leukaemia

J. Cortes, E. Jabbour, N. Pemmaraju, 2019, British journal of haematology.

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood advances.

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

S. Verstovsek, C. Brooks, A. Tefferi, 2021, Blood.

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Clinical lymphoma, myeloma & leukemia.

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

J. Issa, W. Chung, H. Kantarjian, 2013 .

Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects.

G. Hortobagyi, M. Munsell, S. Giordano, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies

J. Radich, T. Lion, J. Cortes, 2020, Hematological oncology.

Identification of a cryptic IRF2BP2-RARA fusion in acute promyelocytic leukemia

Farhad, Ginsberg, L. Chin, 2018 .

Molecular Insights in Patient Care Identification of a Novel Fusion Gene , IRF 2 BP 2-RARA , in Acute Promyelocytic Leukemia

L. Chin, A. Protopopov, Jianhua Zhang, 2015 .

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

P. Sharma, Z. Estrov, J. Blando, 2016 .

The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond

A. Logan, N. Pemmaraju, N. Majhail, 2021, Current Hematologic Malignancy Reports.

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2019, Blood.

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

M. Konopleva, K. Bhalla, H. Kantarjian, 2017, Cancer.

Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial

M. Konopleva, G. Garcia-Manero, T. Kadia, 2015 .

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53

Z. Estrov, H. Kantarjian, K. Patel, 2019, Blood.

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

Naveen Garg, M. Konopleva, Z. Estrov, 2021, Leukemia.

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology.

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

Stephen M. Shaw, M. Andreeff, J. Dipersio, 2020, Cancer.

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms

G. Borthakur, N. Pemmaraju, N. Chen, 2020, Leukemia & lymphoma.

Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia.

Z. Estrov, J. Cortes, A. Quintás-Cardama, 2013, Clinical lymphoma, myeloma & leukemia.

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

T. Choueiri, N. Agarwal, B. Halmos, 2021, Nature Reviews Clinical Oncology.

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

M. Konopleva, N. Pemmaraju, M. Alfayez, 2019, Expert opinion on biological therapy.

Glioblastoma and acute myeloid leukemia: malignancies with striking similarities

G. Rao, N. Pemmaraju, B. Carter, 2017, Journal of Neuro-Oncology.

Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN

M. Konopleva, A. Lane, K. Stevenson, 2021, Blood.

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2020, Blood.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

FLT3 inhibitors in the treatment of acute myeloid leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2011, Cancer.

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Xiang Li, J. Goldberg, M. Grunwald, 2022, Clinical and translational science.

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.

M. Konopleva, H. Kantarjian, A. Lane, 2022, Blood.

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

P. Vyas, M. Konopleva, G. Gaidano, 2022, Blood.

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

A. Lane, C. Brooks, N. Pemmaraju, 2022, Blood.

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

M. Konopleva, N. Pemmaraju, M. Frattini, 2022, Blood.

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

M. Konopleva, A. Lane, C. Brooks, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy.

S. Meshinchi, N. Pemmaraju, E. Angelucci, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

AML-465 Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement.

M. Konopleva, H. Kantarjian, A. Lane, 2021, Clinical Lymphoma, Myeloma & Leukemia.

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2021, Blood.

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

M. Konopleva, M. Andreeff, K. Bhalla, 2022, Blood advances.

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Questions on asparaginase-associated pancreatitis.

N. Pemmaraju, M. Rytting, 2017, The Lancet. Oncology.

FLT3-ITD. Clinical (Sorafenib/AC220)

J. Cortes, N. Pemmaraju, 2015 .

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Blood.

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021 .

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.

C. Mullighan, M. Konopleva, H. Kantarjian, 2020, The Lancet. Haematology.

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Cancer.

Blastic plasmacytoid dendritic cell neoplasm.

N. Pemmaraju, 2016, Clinical advances in hematology & oncology : H&O.

Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel

S. Pileri, A. Órfão, L. Pagano, 2023, HemaSphere.

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Cancer.

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2021, Haematologica.

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)

G. Garcia-Manero, T. Kadia, F. Ravandi, 2021, Blood.

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Blood.

A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Cancer.

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

M. Konopleva, K. Patel, D. Kipp, 2022, Blood.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Cancer.

Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)

T. Kadia, P. Jain, F. Ravandi, 2020, Leukemia & lymphoma.

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.

V. Baladandayuthapani, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Leukemia.

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.

M. Konopleva, Z. Estrov, G. Garcia-Manero, 2021, Blood Advances.

Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

P. A. Futreal, S. Ogawa, Jianhua Zhang, 2018, Blood.

Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature

J. Cortes, N. Pemmaraju, 2014, Acta Haematologica.

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012, Haematologica.

A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.

M. Konopleva, A. Lane, G. Martinelli, 2020 .

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, The Lancet. Haematology.

CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.

J. Khoury, N. Pemmaraju, N. Jain, 2022, Leukemia research.

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia.

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Haematologica.

Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM

R. Mesa, N. Pemmaraju, Vikas Gupta, 2015, Current Hematologic Malignancy Reports.

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

M. Konopleva, Z. Estrov, H. Kantarjian, 2020 .

Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

M. Konopleva, M. Andreeff, K. Bhalla, 2020 .

Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.

N. Pemmaraju, M. Abboud, N. Tarek, 2022, Leukemia research reports.

Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)

P. A. Futreal, Hannah C. Beird, M. Konopleva, 2019, Blood Cancer Journal.

Early detection of transformation to BPDCN in a patient with MDS

M. Konopleva, M. Andreeff, T. Kadia, 2018, Experimental Hematology & Oncology.

Heterogeneous JAK2V617F Allele Burden in Essential Thrombocytosis: Gender and Clinical Correlates.

N. Pemmaraju, J. Spivak, A. Moliterno, 2006 .

Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm

Siba El Hussein, M. Konopleva, J. Khoury, 2022, Cancers.

Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin

Hannah C. Beird, M. Dennis, T. Somervaille, 2021, Leukemia.

Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

S. Verstovsek, C. Brooks, M. Talpaz, 2020 .

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Jacqueline S. Garcia, R. Mesa, C. Harrison, 2019, Blood.

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

E. Burton, H. Kantarjian, J. Cortes, 2011 .

Chronic Myelomonocytic Leukemia: Hematopathology Perspective.

J. Khoury, N. Pemmaraju, Sa A. Wang, 2021, Journal of immunotherapy and precision oncology.

Real-world treatments and thrombotic events in polycythemia vera patients in the USA

S. Gupta, S. Verstovsek, N. Pemmaraju, 2023, Annals of Hematology.

Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms

J. Radich, T. Barbui, S. Verstovsek, 2019, Hematological oncology.

in blastic plasmacytoid dendritic cell neoplasm patients Activity of SL-401, a targeted therapy directed to interleukin-3 receptor,

M. Konopleva, O. Frankfurt, C. Brooks, 2014 .

Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.

S. Verstovsek, N. Pemmaraju, R. Scherber, 2022, Leukemia research.

Secondary erythrocytosis

S. Verstovsek, N. Pemmaraju, C. Rojas-Hernandez, 2023, Expert review of hematology.

L‐carnitine and Vitamin B Complex for the Treatment of Pegasparaginase‐induced Hyperbilirubinemia

H. Kantarjian, E. Jabbour, N. Pemmaraju, 2018, Clinical lymphoma, myeloma & leukemia.

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia

G. Garcia-Manero, S. Verstovsek, F. Ravandi, 2020, British journal of haematology.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Hoang Q. Nguyen, P. Thall, E. Estey, 2015, Haematologica.

The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette.

R. Mesa, N. Pemmaraju, M. Thompson, 2017, Seminars in hematology.

Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia

T. Kadia, J. Burger, N. Pemmaraju, 2019, Leukemia & lymphoma.

Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant

M. Konopleva, A. Futreal, K. Patel, 2020, Leukemia & lymphoma.

A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Cancer.

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase

M. Konopleva, H. Kantarjian, J. Cortes, 2017 .

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy

Angela G. Fleischman, S. Verstovsek, N. Pemmaraju, 2023, Leukemia & lymphoma.

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

S. Verstovsek, A. Vannucchi, M. McMullin, 2022, EJHaem.

Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020 .

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

S. Devlin, S. Verstovsek, T. Kadia, 2019, Blood.

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

H. Kantarjian, S. Verstovsek, K. Patel, 2019, Blood.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Z. Estrov, K. Bhalla, H. Kantarjian, 2018, Blood.

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Z. Estrov, M. Andreeff, H. Kantarjian, 2021, Blood.

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm

M. Konopleva, K. Bhalla, M. J. You, 2021, Cancers.

Association between bariatric surgery and outcomes in chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, Cancer.

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2019, Blood.

Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, bioRxiv.

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Naveen Garg, Catherine J. Wu, P. Sharma, 2022, Blood advances.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2023, The Lancet. Haematology.

Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2013 .

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

M. Konopleva, H. Kantarjian, T. Kadia, 2019, Blood.

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.

S. Mustjoki, M. Konopleva, M. Andreeff, 2023, Haematologica.

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Blood.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, American journal of hematology.

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm

Hannah C. Beird, M. Konopleva, A. Futreal, 2023, Blood advances.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Hannah C. Beird, M. Konopleva, H. Kantarjian, 2019, Blood.

Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, R. Galetto, H. Kantarjian, 2016 .

Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, K. Rezvani, E. Shpall, 2021, Bone Marrow Transplantation.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms

W. R. Burack, L. Medeiros, J. Liesveld, 2022, EJHaem.

Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon

L. Medeiros, J. Khoury, N. Pemmaraju, 2021, Leukemia & lymphoma.

Targeting the p-D-C: easy as C-D-1-2-3?

N. Pemmaraju, 2021, Blood.

Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a ten-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm

L. Medeiros, Shaoying Li, J. Khoury, 2020, Haematologica.

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for BPDCN

M. Konopleva, U. Popat, Q. Bashir, 2020 .

Treatment advances in blastic plasmacytoid dendritic cell neoplasm.

N. Pemmaraju, 2019, Clinical advances in hematology & oncology : H&O.

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2018, Blood.

Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2020 .

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology/oncology.

Early-Onset GI Cancers: Rising Trends, Genetic Risks, Novel Strategies, and Special Considerations.

N. Pemmaraju, E. Harrold, C. Lieu, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer

W. Wood, M. Perales, N. Pemmaraju, 2016, Current Hematologic Malignancy Reports.

Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media—#MPNSM

Naveen Pemmaraju, R. Mesa, N. Pemmaraju, 2017, Current Hematologic Malignancy Reports.

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN

A. Lane, N. Pemmaraju, Vikas Gupta, 2017, Current Hematologic Malignancy Reports.

Disease-specific hashtags and the creation of Twitter medical communities in hematology and oncology.

Naveen Pemmaraju, M. Qazilbash, N. Pemmaraju, 2017, Seminars in hematology.

Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends.

Tejas Desai, Naveen Pemmaraju, R. Mesa, 2017, Journal of oncology practice.

Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)

Hui Yang, Simona Colla, Xuelin Huang, 2016 .

Social Media for Hematopathologists: Medical Practice Reinvented—#Hemepath

L. Medeiros, J. Khoury, N. Pemmaraju, 2020, Current Hematologic Malignancy Reports.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community

A. Lane, N. Pemmaraju, Vikas Gupta, 2018, Current Hematologic Malignancy Reports.

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2016 .

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy

E. Burton, H. Kantarjian, J. Cortes, 2011 .

A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Blood.

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response

P. Sharma, M. Konopleva, M. Andreeff, 2020 .

The role of therapy in the outcome of patients with myelofibrosis

Z. Estrov, H. Kantarjian, S. Verstovsek, 2023, Cancer.

Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Ocular extramedullary myeloid leukaemia

Z. Estrov, J. Manning, F. Ravandi, 2018, British journal of haematology.

Early Treatment with Ofatumumab in Patients with High-Risk CLL

M. Konopleva, Z. Estrov, T. Kadia, 2022, Blood.

Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

G. Garcia-Manero, J. Cortes, T. Kadia, 2022, American journal of hematology.

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

G. Garcia-Manero, S. Dakhil, N. Pemmaraju, 2018, Blood.

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

M. Konopleva, K. Bhalla, H. Kantarjian, 2023, Haematologica.

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements.

C. Mullighan, K. Patel, T. Kadia, 2023, JCO precision oncology.

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

M. Konopleva, H. Kantarjian, T. Kadia, 2020 .

Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations

M. Konopleva, M. Andreeff, H. Kantarjian, 2018, Blood.

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms.

M. Konopleva, A. Lane, N. Pemmaraju, 2019, The New England journal of medicine.

neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm

Shaoying, L. Medeiros, J. Khoury, 2020 .

Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017 .

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD

Naveen Garg, T. Kadia, M. Keating, 2023, Leukemia.

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

J. Welch, M. Konopleva, M. Andreeff, 2019, Blood.

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology/oncology.

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

S. Verstovsek, R. Hoffman, N. Pemmaraju, 2021, Blood.

Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

M. Konopleva, Z. Estrov, H. Kantarjian, 2020 .

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

M. Konopleva, G. Garcia-Manero, T. Kadia, 2022, Blood.

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2021, Blood.

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, Blood.

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

G. Garcia-Manero, C. Brooks, A. Tefferi, 2021, Blood.

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, Leukemia.

Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2020 .

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016, Blood.

Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations

S. Verstovsek, M. Routbort, K. Patel, 2022, Modern Pathology.

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

M. Konopleva, K. Bhalla, H. Kantarjian, 2018, Blood.

Chronic myelomonocytic leukemia: Forefront of the field in 2015

G. Garcia-Manero, N. Pemmaraju, A. Nazha, 2016 .

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.

S. Verstovsek, C. Brooks, M. Talpaz, 2019, Journal of Clinical Oncology.

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

S. Verstovsek, C. Brooks, M. Talpaz, 2018, Blood.

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).

S. Verstovsek, C. Brooks, M. Talpaz, 2019, Journal of Clinical Oncology.

New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐XL/BCL‐2 inhibition with navitoclax

Jacqueline S. Garcia, F. Passamonti, N. Pemmaraju, 2023, Cancer.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

K. Rajapakshe, C. Coarfa, M. Konopleva, 2019, Blood Cancer Journal.

A Single Case of Rosai–Dorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine

D. Podoloff, G. Borthakur, N. Daver, 2014, Front. Oncol..

Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies.

S. Meshinchi, S. Garcés, N. Pemmaraju, 2023, Leukemia.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

G. Garcia-Manero, K. Patel, G. Borthakur, 2022, Blood.

Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy

N. Pemmaraju, Joseph L. Lasky, N. Hijiya, 2021, Blood.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.

N. Pemmaraju, Michael Roth, Branko Cuglievan, 2023, Journal of pediatric hematology/oncology.

Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, British journal of haematology.

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia

G. Borthakur, N. Pemmaraju, N. Jain, 2014, European journal of haematology.

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, British journal of haematology.

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL).

Naveen Garg, M. Konopleva, Z. Estrov, 2019, Blood.

Patient with mixed-phenotype acute leukemia with CBFB rearrangement

G. Borthakur, J. Khoury, N. Pemmaraju, 2019, Leukemia & lymphoma.

S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION

M. Konopleva, Z. Estrov, T. Kadia, 2022, HemaSphere.

Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.

H. Kantarjian, J. Cortes, F. Ravandi, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Leukemia & lymphoma.

Philadelphia–positive dimorphic blasts in mixed‐phenotype acute leukemia with TET2 mutation

Z. Estrov, P. Jain, N. Daver, 2016, American journal of hematology.

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.

K. Patel, T. Kadia, E. Jabbour, 2023, American journal of hematology.

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2021, Frontiers in Oncology.

Erythroleukemia-historical perspectives and recent advances in diagnosis and management.

G. Borthakur, J. Khoury, N. Pemmaraju, 2017, Blood reviews.

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Haematologica.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, The Lancet. Haematology.

FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status.

M. Konopleva, M. Andreeff, H. Kantarjian, 2009 .

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015 .

P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

T. Kadia, F. Ravandi, E. Jabbour, 2022, HemaSphere.

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2020 .

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, Blood.

Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, American journal of hematology.

Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors

S. Verstovsek, N. Pemmaraju, M. Economides, 2019, Current Hematologic Malignancy Reports.

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

H. Kantarjian, F. Ravandi, E. Jabbour, 2023, Blood.

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

S. Kornblau, M. Andreeff, F. Ravandi, 2022, HemaSphere.

VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field.

N. Pemmaraju, E. Groarke, Luan Phan, 2024, Leukemia & lymphoma.

BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial

M. Andreeff, O. Frankfurt, A. Nagler, 2014 .

Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.

N. Pemmaraju, L. Masarová, J. Kiladjian, 2024, British journal of haematology.

Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.

K. Bhalla, G. Garcia-Manero, T. Kadia, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis

H. Kantarjian, G. Garcia-Manero, Koichi Takahashi, 2022, American journal of hematology.

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.

Xiaoping Su, K. Bhalla, T. Kadia, 2023, Leukemia.